Safety of azithromycin in infants under six months of age in Niger: A community randomized trial

Catherine E Oldenburg, Ahmed M Arzika, Ramatou Maliki, Mohamed Salissou Kane, Elodie Lebas, Kathryn J Ray, Catherine Cook, Sun Y Cotter, Zhaoxia Zhou, Sheila K West, Robin Bailey, Travis C Porco, Jeremy D Keenan, Thomas M Lietman, MORDOR Study Group, Catherine E Oldenburg, Ahmed M Arzika, Ramatou Maliki, Mohamed Salissou Kane, Elodie Lebas, Kathryn J Ray, Catherine Cook, Sun Y Cotter, Zhaoxia Zhou, Sheila K West, Robin Bailey, Travis C Porco, Jeremy D Keenan, Thomas M Lietman, MORDOR Study Group

Abstract

Background: Mass azithromycin distribution reduces under-5 child mortality. Trachoma control programs currently treat infants aged 6 months and older. Here, we report findings from an infant adverse event survey in 1-5 month olds who received azithromycin as part of a large community-randomized trial in Niger.

Methods and principal findings: Active surveillance of infants aged 1-5 months at the time of treatment was conducted in 30 randomly selected communities from within a large cluster randomized trial of biannual mass azithromycin distribution compared to placebo to assess the potential impact on child mortality. We compared the distribution of adverse events reported after treatment among azithromycin-treated versus placebo-treated infants. From January 2015 to February 2018, the caregivers of 1,712 infants were surveyed. Approximately one-third of caregivers reported at least one adverse event (azithromycin: 29.6%, placebo: 34.3%, risk ratio [RR] 0.86, 95% confidence interval [CI] 0.68 to 1.10, P = 0.23). The most commonly reported adverse events included diarrhea (azithromycin: 19.3%, placebo: 28.1%, RR 0.68, 95% CI 0.49 to 0.96, P = 0.03), vomiting (azithromycin: 15.9%, placebo: 21.0%, RR 0.76, 95% CI 0.56 to 1.02, P = 0.07), and skin rash (azithromycin: 12.3%, placebo: 13.6%, RR 0.90, 95% CI 0.59 to 1.37, P = 0.63). No cases of infantile hypertrophic pyloric stenosis were reported.

Conclusions: Azithromycin given to infants aged 1-5 months appeared to be safe. Inclusion of younger infants in larger azithromycin-based child mortality or trachoma control programs could be considered if deemed effective.

Trial registration: ClinicalTrials.gov NCT02048007.

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1. CONSORT diagram for the trial.
Fig 1. CONSORT diagram for the trial.

References

    1. International Trachoma Initiative: Frequently Asked Questions. .
    1. Emerson PM, Hooper PJ, Sarah V. Progress and projections in the program to eliminate trachoma. PLoS Negl Trop Dis 2017; 11: e0005402–4.
    1. Chidambaram JD, Alemayehu W, Melese M, et al. Effect of a Single Mass Antibiotic Distribution on the Prevalence of Infectious Trachoma. JAMA 2006; 295: 1142–6.
    1. Solomon AW, Holland MJ, Alexander ND, et al. Mass Treatment with Single-Dose Azithromycin for Trachoma. N Engl J Med 2004; 351: 1962–71.
    1. Amza A, Kadri B, Nassirou B, et al. A cluster-randomized trial to assess the efficacy of targeting trachoma treatment to children. Clin Infect Dis 2017; 64: 743–50.
    1. Melese M, Alemayehu W, Lakew T, et al. Comparison of Annual and Biannual Mass Antibiotic Administration for Elimination of Infectious Trachoma. JAMA 2008; 299: 778–84.
    1. House JI, Ayele B, Porco TC, et al. Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster-randomisedtrial. The Lancet 2009; 373: 1111–8.
    1. Smith C, Egunsola O, Choonara I, Kotecha S, Jacqz-Aigrain E, Sammons H. Use and safety of azithromycin in neonates: a systematic review. BMJ Open 2015; 5: e008194–8.
    1. Eberly MD, Eide MB, Thompson JL, Nylund CM. Azithromycin in Early Infancy and Pyloric Stenosis. Pediatrics 2015; 135: 483–8.
    1. Lund M, Pasternak B, Davidsen RB, et al. Use of macrolides in mother and child and risk of infantile hypertrophic pyloric stenosis: nationwide cohort study. BMJ 2014; 348: g1908–8.
    1. Murchison L, Coppi P, Eaton S. Post-natal erythromycin exposure and risk of infantile hypertrophic pyloric stenosis: a systematic review and meta-analysis. Pediatric Surgery International 2016; 32: 1147–52.
    1. Last A, Burr S, Alexander N, et al. Spatial clustering of high load ocular Chlamydia trachomatis infection in trachoma: a cross-sectional population-based study. Pathogens and Disease 2017; 75: 175–10.
    1. Keenan JD, Bailey RL, West SK, et al. Mass azithromycin distribution for reducing childhood mortality in sub-Saharan Africa. N Engl J Med 2018; 378: 1583–92.
    1. Yusuf S, Collins R, Peto R. Why do we need some large, simple trials? Statistics in Medicine 1984; 3: 409–20.
    1. Melese M, Chidambaram JD, Alemayehu W, et al. Feasibility of Eliminating Ocular Chlamydia trachomatis With Repeat Mass Antibiotic Treatments. JAMA 2004; 292: 721–5.
    1. Ballard HO, Anstead MI, Shook LA. Azithromycin in the extremely low birth weight infant for the prevention of Bronchopulmonary Dysplasia: a pilot study. Respir Res 2007; 8: 1793–9.
    1. Ballard HO, Shook LA, Bernard P, et al. Use of azithromycin for the prevention of bronchopulmonary dysplasia in preterm infants: a randomized, double-blind, placebo controlled trial. Pediatr Pulmonol 2010; 46: 111–8.
    1. Gharehbaghi MM, Peirovifar A, Ghojazadeh M, Mahallei M. Efficacy of azithromycin for prevention of bronchopulmonary dysplasia (BPD). Turk J Med Sci 2012; 42: 1070–5.
    1. Nair V, Loganathan P, Soraisham AS. Azithromycin and Other Macrolides for Prevention of Bronchopulmonary Dysplasia: A Systematic Review and Meta-Analysis. Neonatology 2014; 106: 337–47.
    1. Schechter R, Torfs CP, Bateson TF. The epidemiology of infantile hypertrophic pyloric stenosis. Pediatric and Perinatal Epidemiology 1997; 11: 407–27.
    1. Zhu J, Zhu T, Lin Z, Qu Y, Mu D. Perinatal risk factors for infantile hypertrophic pyloric stenosis: A meta-analysis. Journal of Pediatric Surgery 2017; 52: 1389–97.
    1. Krogh C, Biggar RJ, Fischer TK, Lindholm M, Wohlfahrt J, Melbye M. Bottle-feeding and the Risk of Pyloric Stenosis. Pediatrics 2012; 130: e943–9.
    1. Wayne C, Hung J-HC, Chan E, Sedgwick I, Bass J, Nasr A. Formula-feeding and hypertrophic pyloric stenosis: is there an association? A case–control study. Journal of Pediatric Surgery 2016; 51: 779–82.
    1. Oluwalana C, Camara B, Bottomley C, et al. Azithromycin in Labor Lowers Clinical Infections in Mothers and Newborns: A Double-Blind Trial. Pediatrics 2017; 139: e20162281
    1. West SK, Stare D, Mkocha H, Munoz B, Gaydos C, Quinn TC. Do Infants Increase the Risk of Re-emergent Infection in Households after Mass Drug Administration for Trachoma? Investigative ophthalmology & visual science 2011; 52: 6040–3.
    1. Mabey DC, Downes RM, Downes B, Bailey RL, Dunn DT. The impact of medical services on trachoma in a Gambian village: antibiotics alone are not the answer. Ann Trop Paediatr 1991; 11: 295–300.
    1. Tabbara KF, Abu El-Asrar AM, Al-Omar O, Choudhury AH, Al-Faisal Z. Single-dose Azithromycin in the Treatment of Trachoma: A Randomized, Controlled Study. Ophthalmology 1996; 103: 842–6.
    1. Fraser-Hurt N, Bailey RL, Cousens S, Mabey D, Faal H, Mabey DCW. Efficacy of oral azithromycin versus topical tetracycline in mass treatment of endemic trachoma. Bull World Health Organ 2001; 79: 632–40.
    1. Porco TC, Gebre T, Ayele B, et al. Effect of Mass Distribution of Azithromycin for Trachoma Control on Overall Mortality in Ethiopian Children: A Randomized Trial. JAMA 2009; 302: 962–8.
    1. Keenan JD, Ayele B, Gebre T, et al. Childhood mortality in a cohort treated with mass azithromycin for trachoma. Clin Infect Dis 2011; 52: 883–8.
    1. OBrien KS, Cotter SY, Amza A, et al. Childhood Mortality After Mass Distribution of Azithromycin. The Pediatric Infectious Disease Journal 2018;: 1–24.
    1. Wang H, Bhutta ZA, Coates MM, et al. Global, regional, national, and selected subnational levels of stillbirths, neonatal, infant, and under-5 mortality, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. The Lancet 2016; 388: 1725–74.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren